Key Takeaways In a small trial, 8 of 16 patients responded well to the mRNA vaccineThe vaccine is personalized, based on each patient’s tumorLarger trials are underway to confirm the vaccine’s role in ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™for all indicationsmatching the reference product ...

Robust immune responses were observed among healthy and high-risk younger adults who received the Ad26/protein RSV preF vaccine.

D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...